Literature DB >> 24325584

Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients.

Rocio de la Iglesia1, Patricia Lopez-Legarrea, Ana B Crujeiras, Maria Pardo, Felipe F Casanueva, Maria A Zulet, Jose A Martinez.   

Abstract

OBJECTIVE: A recently discovered myokine, irisin, may have an important role in energy metabolism. This study aimed to evaluate the relationship between this hormone and the lipid profile of patients with metabolic syndrome (MetS) following a hypocaloric diet.
DESIGN: Ninety-three Caucasian adults (52 men/41 women) diagnosed with MetS followed an 8-week-long energy-restricted programme (-30% of the energy requirements). Anthropometric measurements, biochemical markers and plasma irisin levels were analysed before and after the nutritional intervention.
RESULTS: Global plasma irisin levels were significantly reduced at the end of the study (-72.0 ± 100.9 ng/ml, P < 0.001) accompanying the weight loss (-6.9%). The depletion of irisin significantly correlated with changes in some atherogenic-related variables: total cholesterol (B = 0.106, P = 0.018), total cholesterol/high-density lipoprotein cholesterol ratio (B = 0.002, P = 0.036), low-density lipoprotein cholesterol (B = 0.085, P = 0.037) and apolipoprotein B (B = 0.052, P = 0.002), independently of changes in body weight.
CONCLUSIONS: An association between the reduction in plasma irisin levels and the depletion of important lipid metabolism biomarkers was observed in patients with MetS undergoing an energy-restricted programme.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24325584     DOI: 10.1111/cen.12383

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  27 in total

1.  Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk.

Authors:  Grigorios Panagiotou; Lin Mu; Brian Na; Kenneth J Mukamal; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-06-09       Impact factor: 8.694

2.  Circulating irisin and glucose metabolism in overweight/obese women: effects of α-lipoic acid and eicosapentaenoic acid.

Authors:  A E Huerta; P L Prieto-Hontoria; M Fernández-Galilea; N Sáinz; M Cuervo; J A Martínez; M J Moreno-Aliaga
Journal:  J Physiol Biochem       Date:  2015-03-28       Impact factor: 4.158

Review 3.  Chronic Exercise Training and Circulating Irisin in Adults: A Meta-Analysis.

Authors:  Shanhu Qiu; Xue Cai; Zilin Sun; Uwe Schumann; Martina Zügel; Jürgen Michael Steinacker
Journal:  Sports Med       Date:  2015-11       Impact factor: 11.136

4.  Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state?

Authors:  Beatriz García-Fontana; Rebeca Reyes-García; Sonia Morales-Santana; Verónica Ávila-Rubio; Araceli Muñoz-Garach; Pedro Rozas-Moreno; Manuel Muñoz-Torres
Journal:  Endocrine       Date:  2015-10-05       Impact factor: 3.633

5.  Myricanol modulates skeletal muscle-adipose tissue crosstalk to alleviate high-fat diet-induced obesity and insulin resistance.

Authors:  Shengnan Shen; Qiwen Liao; Tian Zhang; Ruile Pan; Ligen Lin
Journal:  Br J Pharmacol       Date:  2019-10-14       Impact factor: 8.739

6.  INFLUENCE OF GLYCEMIC CONTROL AND BODY COMPOSITION ON IRISIN LEVELS IN CHILDREN WITH TYPE 1 DIABETES MELLITUS.

Authors:  S E Beray; M E Atabek; Y Kücükkagnici; S Kurban; M B Selver; M S Iyisoy
Journal:  Acta Endocrinol (Buchar)       Date:  2022 Jan-Mar       Impact factor: 1.104

7.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

8.  Decreased Concentration of Irisin Is Associated with Poor Functional Outcome in Ischemic Stroke.

Authors:  Wen-Jun Tu; Han-Cheng Qiu; Jian-Lei Cao; Qiang Liu; Xian-Wei Zeng; Ji-Zong Zhao
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 9.  Irisin: a new molecular marker and target in metabolic disorder.

Authors:  Jia-qi Chen; Yue-ye Huang; Aaron M Gusdon; Shen Qu
Journal:  Lipids Health Dis       Date:  2015-01-14       Impact factor: 3.876

10.  Cardiometabolic health, visceral fat and circulating irisin levels: results from a real-world weight loss study.

Authors:  T Miazgowski; A Kaczmarkiewicz; B Miazgowski; J Kopeć
Journal:  J Endocrinol Invest       Date:  2020-09-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.